Clinical Trial Update: Safety and Efficacy of Berodual® Respimat® Compared to Berodual® MDI (Metered Dose Inhaler) in Asthma Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Berodual Respimat to Berodual MDI in asthma patients has completed, evaluating safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Berodual MDI (ipratropium bromide and fenoterol hydrobromide)
• Berodual Respimat (ipratropium bromide and fenoterol hydrobromide)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Asthma | Phase 3 | Status: COMPLETED